TISIDB

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm
Domain	PF00179 Ubiquitin-conjugating enzyme
Function	The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes.

> Gene Ontology [ TOP ]
Biological Process	GO:0000209 protein polyubiquitination GO:0000724 double-strand break repair via homologous recombination GO:0000725 recombinational repair GO:0000726 non-recombinational repair GO:0000729 DNA double-strand break processing GO:0002218 activation of innate immune response GO:0002220 innate immune response activating cell surface receptor signaling pathway GO:0002221 pattern recognition receptor signaling pathway GO:0002223 stimulatory C-type lectin receptor signaling pathway GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002753 cytoplasmic pattern recognition receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006282 regulation of DNA repair GO:0006289 nucleotide-excision repair GO:0006301 postreplication repair GO:0006302 double-strand break repair GO:0006303 double-strand break repair via nonhomologous end joining GO:0006310 DNA recombination GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0016570 histone modification GO:0016574 histone ubiquitination GO:0030522 intracellular receptor signaling pathway GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031349 positive regulation of defense response GO:0031396 regulation of protein ubiquitination GO:0031398 positive regulation of protein ubiquitination GO:0033182 regulation of histone ubiquitination GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway GO:0038093 Fc receptor signaling pathway GO:0038095 Fc-epsilon receptor signaling pathway GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045739 positive regulation of DNA repair GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051438 regulation of ubiquitin-protein transferase activity GO:0051443 positive regulation of ubiquitin-protein transferase activity GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway GO:0070534 protein K63-linked ubiquitination GO:0070911 global genome nucleotide-excision repair GO:1902275 regulation of chromatin organization GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903322 positive regulation of protein modification by small protein conjugation or removal GO:1905269 positive regulation of chromatin organization GO:2001020 regulation of response to DNA damage stimulus GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function	GO:0004842 ubiquitin-protein transferase activity GO:0019787 ubiquitin-like protein transferase activity GO:0031625 ubiquitin protein ligase binding GO:0032182 ubiquitin-like protein binding GO:0043130 ubiquitin binding GO:0044389 ubiquitin-like protein ligase binding GO:0061630 ubiquitin protein ligase activity GO:0061631 ubiquitin conjugating enzyme activity GO:0061650 ubiquitin-like protein conjugating enzyme activity GO:0061659 ubiquitin-like protein ligase activity
Cellular Component	GO:0000151 ubiquitin ligase complex GO:0031371 ubiquitin conjugating enzyme complex GO:0031372 UBC13-MMS2 complex GO:0035370 UBC13-UEV1A complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04120 Ubiquitin mediated proteolysis
Reactome	R-HSA-166054: Activated TLR4 signalling R-HSA-1280218: Adaptive Immune System R-HSA-983168: Antigen processing R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5607764: CLEC7A (Dectin-1) signaling R-HSA-1640170: Cell Cycle R-HSA-69620: Cell Cycle Checkpoints R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-5693606: DNA Double Strand Break Response R-HSA-5693532: DNA Double-Strand Break Repair R-HSA-73894: DNA Repair R-HSA-202424: Downstream TCR signaling R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins R-HSA-2871837: FCERI mediated NF-kB activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-5696395: Formation of Incision Complex in GG-NER R-HSA-69481: G2/M Checkpoints R-HSA-69473: G2/M DNA damage checkpoint R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER) R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) R-HSA-5693538: Homology Directed Repair R-HSA-937041: IKK complex recruitment mediated by RIP1 R-HSA-937039: IRAK1 recruits IKK complex R-HSA-975144: IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation R-HSA-1169408: ISG15 antiviral mechanism R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-913531: Interferon Signaling R-HSA-446652: Interleukin-1 signaling R-HSA-450321: JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 R-HSA-450294: MAP kinase activation in TLR cascade R-HSA-392499: Metabolism of proteins R-HSA-975871: MyD88 cascade initiated on plasma membrane R-HSA-975155: MyD88 dependent cascade initiated on endosome R-HSA-166166: MyD88-independent TLR3/TLR4 cascade R-HSA-166058: MyD88 R-HSA-168638: NOD1/2 Signaling Pathway R-HSA-5693571: Nonhomologous End-Joining (NHEJ) R-HSA-5696398: Nucleotide Excision Repair R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways R-HSA-597592: Post-translational protein modification R-HSA-5693607: Processing of DNA double-strand break ends R-HSA-8852135: Protein ubiquitination R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks R-HSA-449147: Signaling by Interleukins R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex R-HSA-202403: TCR signaling R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines R-HSA-975110: TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade R-HSA-168179: Toll Like Receptor TLR1 R-HSA-168188: Toll Like Receptor TLR6 R-HSA-168898: Toll-Like Receptors Cascades R-HSA-450302: activated TAK1 mediates p38 MAPK activation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04120 Ubiquitin mediated proteolysis

Reactome

R-HSA-166054: Activated TLR4 signalling
R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-5693606: DNA Double Strand Break Response
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-202424: Downstream TCR signaling
R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-2871837: FCERI mediated NF-kB activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-5696395: Formation of Incision Complex in GG-NER
R-HSA-69481: G2/M Checkpoints
R-HSA-69473: G2/M DNA damage checkpoint
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5693538: Homology Directed Repair
R-HSA-937041: IKK complex recruitment mediated by RIP1
R-HSA-937039: IRAK1 recruits IKK complex
R-HSA-975144: IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
R-HSA-1169408: ISG15 antiviral mechanism
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-446652: Interleukin-1 signaling
R-HSA-450321: JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-392499: Metabolism of proteins
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-168638: NOD1/2 Signaling Pathway
R-HSA-5693571: Nonhomologous End-Joining (NHEJ)
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-597592: Post-translational protein modification
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-8852135: Protein ubiquitination
R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
R-HSA-449147: Signaling by Interleukins
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-202403: TCR signaling
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975110: TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-450302: activated TAK1 mediates p38 MAPK activation

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between UBE2N and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of UBE2N in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.47; FDR: 0.01650	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of UBE2N in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.113	0.507
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.341	0.895
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.052	0.978
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.154	0.712
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.387	0.812
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.837	0.68
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.134	0.735
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.241	0.896
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.01	0.996
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.061	0.972
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.019	0.994
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.099	0.11

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of UBE2N in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE2N. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE2N. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE2N. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE2N. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of UBE2N expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between UBE2N and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	UBE2N
Name	ubiquitin-conjugating enzyme E2N
Aliases	UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting UBE2N collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse UBE2N